These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 22640784)

  • 21. The heartbreak of psoriasis: a review of cardiovascular risk in patients with psoriasis.
    Benson MM; Frishman WH
    Cardiol Rev; 2015; 23(6):312-6. PubMed ID: 26440534
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Psoriasis is a systemic disease with multiple cardiovascular and metabolic comorbidities.
    Ryan C; Kirby B
    Dermatol Clin; 2015 Jan; 33(1):41-55. PubMed ID: 25412782
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cardiovascular disease and risk factors in patients with psoriasis and psoriatic arthritis.
    Tobin AM; Veale DJ; Fitzgerald O; Rogers S; Collins P; O'Shea D; Kirby B
    J Rheumatol; 2010 Jul; 37(7):1386-94. PubMed ID: 20472927
    [TBL] [Abstract][Full Text] [Related]  

  • 24. More than skin deep: atherosclerosis as a systemic manifestation of psoriasis.
    Alexandroff AB; Pauriah M; Camp RD; Lang CC; Struthers AD; Armstrong DJ
    Br J Dermatol; 2009 Jul; 161(1):1-7. PubMed ID: 19500102
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The 'psoriatic march': a concept of how severe psoriasis may drive cardiovascular comorbidity.
    Boehncke WH; Boehncke S; Tobin AM; Kirby B
    Exp Dermatol; 2011 Apr; 20(4):303-7. PubMed ID: 21410760
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognosis following first-time myocardial infarction in patients with psoriasis: a Danish nationwide cohort study.
    Ahlehoff O; Gislason GH; Lindhardsen J; Olesen JB; Charlot M; Skov L; Torp-Pedersen C; Hansen PR
    J Intern Med; 2011 Sep; 270(3):237-44. PubMed ID: 21362070
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cardiovascular risk and psoriasis: the role of biologic therapy.
    Puig L
    Actas Dermosifiliogr; 2012 Dec; 103(10):853-62. PubMed ID: 23157913
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cardiovascular and metabolic risks in psoriasis and psoriatic arthritis: pragmatic clinical management based on available evidence.
    Johnsson H; McInnes IB; Sattar N
    Ann Rheum Dis; 2012 Apr; 71(4):480-3. PubMed ID: 22294632
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Cardiovascular risk in systemic inflammatory diseases].
    Marsico F; Parente A; Paolillo S; Casaretti L; Lo Iudice F; Pirozzi E; Conte S; Iardino E; Gambardella F; Della Ratta GL; Cirillo A; Vitagliano A; Filardi PP
    G Ital Cardiol (Rome); 2013; 14(7-8):517-25. PubMed ID: 23877549
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cardiovascular health for patients with psoriasis: a précis for front-line clinicians.
    Federman DG; Shelling ML; Prodanovich S; Gunderson CG; Kirsner RS
    Ostomy Wound Manage; 2009 May; 55(5):38-47. PubMed ID: 19471047
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of tumor necrosis factor-alpha blockade on metabolic syndrome components in psoriasis and psoriatic arthritis and additional lessons learned from rheumatoid arthritis.
    Channual J; Wu JJ; Dann FJ
    Dermatol Ther; 2009; 22(1):61-73. PubMed ID: 19222518
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Heart disease in psoriasis.
    Kremers HM; McEvoy MT; Dann FJ; Gabriel SE
    J Am Acad Dermatol; 2007 Aug; 57(2):347-54. PubMed ID: 17433490
    [TBL] [Abstract][Full Text] [Related]  

  • 33. GRAPPA 2013 basic/translational/clinical science update: comorbidity monitoring.
    Boehncke WH
    J Rheumatol; 2014 Jun; 41(6):1224-6. PubMed ID: 24882857
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Liver fibrosis in patients with psoriasis and psoriatic arthritis on long-term, high cumulative dose methotrexate therapy.
    Lindsay K; Fraser AD; Layton A; Goodfield M; Gruss H; Gough A
    Rheumatology (Oxford); 2009 May; 48(5):569-72. PubMed ID: 19273538
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Psoriasis and systemic lupus erythematosus: a rare association with specific therapeutic problems].
    Astudillo L; Sailler L; Carreiro M; Dahan S; Ollier S; Arlet P
    Ann Med Interne (Paris); 2003 Feb; 154(1):3-6. PubMed ID: 12746653
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Risk of cardiovascular disorders in psoriasis patients: current and future.
    Tablazon IL; Al-Dabagh A; Davis SA; Feldman SR
    Am J Clin Dermatol; 2013 Feb; 14(1):1-7. PubMed ID: 23329076
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Is psoriasis a dependent cardiovascular risk factor?].
    Wakkee M; de Jong EM
    Ned Tijdschr Geneeskd; 2013; 157(11):A5417. PubMed ID: 23484510
    [TBL] [Abstract][Full Text] [Related]  

  • 38. What's new in the management of psoriasis?
    Kinney MA; Feldman SR
    G Ital Dermatol Venereol; 2009 Apr; 144(2):103-17. PubMed ID: 19357619
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Psoriasis may not be an independent predictor for the use of cardiovascular and anti-diabetic drugs: a 5-year prevalence study.
    Wakkee M; Meijer W; Neumann HA; Herings RM; Nijsten T
    Acta Derm Venereol; 2009; 89(5):476-83. PubMed ID: 19734972
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Psoriasis as an independent risk factor for development of coronary artery disease].
    Papo D; Hein R; Ring J
    Dtsch Med Wochenschr; 2010 Sep; 135(36):1749-54. PubMed ID: 20812162
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.